Ramakrishnan Gopalakrishnan
Overview
Explore the profile of Ramakrishnan Gopalakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choi S, Matta H, Gopalakrishnan R, Natarajan V, Gong S, Jeronimo A, et al.
Sci Rep
. 2021 May;
11(1):10002.
PMID: 33976304
Cytotoxicity assays are essential for the testing and development of novel immunotherapies for the treatment of cancer. We recently described a novel cytotoxicity assay, termed the Matador assay, which was...
2.
Gopalakrishnan R, Matta H, Choi S, Chaudhary P
Sci Rep
. 2020 Apr;
10(1):5712.
PMID: 32235878
Primary effusion lymphoma (PEL) is a subtype of non-Hodgkin lymphoma associated with infection by Kaposi sarcoma-associated herpes virus (KSHV). PEL is an aggressive disease with extremely poor prognosis when treated...
3.
Natarajan V, Gopalakrishnan R, Matta H, Choi S, Gong S, Jeronimo A, et al.
Sci Rep
. 2020 Feb;
10(1):2318.
PMID: 32047180
Success of immunotherapeutic approaches using genetically engineered antibodies and T cells modified with chimeric antigen receptors (CARs) depends, among other things, on the selection of antigen binding domains with desirable...
4.
Gopalakrishnan R, Matta H, Choi S, Natarajan V, Prins R, Gong S, et al.
Sci Rep
. 2019 Feb;
9(1):1957.
PMID: 30760795
Chimeric Antigen Receptor-T (CAR-T) cell immunotherapy has produced dramatic responses in hematologic malignancies. One of the challenges in the field is the lack of a simple assay for the detection...
5.
Matta H, Gopalakrishnan R, Choi S, Prakash R, Natarajan V, Prins R, et al.
Sci Rep
. 2018 Jan;
8(1):199.
PMID: 29317736
A simple, accurate, sensitive and robust assay that can rapidly and specifically measure the death of target cells would have applications in many areas of biomedicine and particularly for the...
6.
Tolani B, Matta H, Gopalakrishnan R, Punj V, Chaudhary P
J Virol
. 2014 Mar;
88(11):6345-54.
PMID: 24672029
Unlabelled: Kaposi's sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 was originally believed to protect virally infected cells against death receptor-induced apoptosis by interfering with caspase 8/FLICE activation. Subsequent studies...
7.
Gopalakrishnan R, Matta H, Chaudhary P
Clin Cancer Res
. 2013 Jul;
19(18):5016-26.
PMID: 23881928
Purpose: Kaposi sarcoma-associated herpes virus (KSHV)-associated primary effusion lymphomas (PEL) have extremely poor prognosis when treated with conventional chemotherapy. KSHV-encoded viral FLICE-inhibitory protein (vFLIP) K13 binds to the IkappaB kinase...
8.
Gopalakrishnan R, Sundaram J, Sattu K, Pandi A, Thiruvengadam D
Mol Cell Biochem
. 2013 Feb;
377(1-2):163-76.
PMID: 23397134
Hepatocellular carcinoma (HCC) incidence rates are increasing in many parts of the world. HCC's limited treatment remedies and the poor prognosis emphasize the importance in developing an effective chemoprevention for...
9.
Matta H, Gopalakrishnan R, Graham C, Tolani B, Khanna A, Yi H, et al.
PLoS One
. 2012 May;
7(5):e36601.
PMID: 22590573
Background: Kaposi's sarcoma associated herpesvirus encoded viral FLICE inhibitory protein (vFLIP) K13 activates the NF-κB pathway by binding to the NEMO/IKKγ subunit of the IκB kinase (IKK) complex. However, it...
10.
Sen P, Clark C, Gopalakrishnan R, Hedner U, Esmon C, Pendurthi U, et al.
Thromb Haemost
. 2012 Feb;
107(5):951-61.
PMID: 22370814
Recent in vitro studies have shown that the zymogen and activated form of factor (F)VII bind to endothelial cell protein C receptor (EPCR). At present, there is no evidence that...